Latest news with #Hafnia
Business Wire
11-07-2025
- Business
- Business Wire
Hafnia Announces Signing of USD 715M Revolving Credit Facility
SINGAPORE--(BUSINESS WIRE)--Hafnia Limited ('Hafnia', the 'Company', OSE ticker code: 'HAFNI', NYSE ticker code: 'HAFN') is pleased to announce the signing of a USD 715 million Revolving Credit Facility (the 'Loan Facility') on 10 July 2025 secured by a modern fleet of 32 product tankers. The facility has a very competitive margin with a tenor of seven years and an age-adjusted amortisation profile of 20 years, was established in partnership with a syndicate of 11 banks. "The lower cost, attractive terms and revolving nature of the facility gives us the agility to manage our liquidity needs and enhance our financial flexibility," says Hafnia's CFO Perry van Echtelt. The syndicate comprises of ING, OCBC, and Standard Chartered as the mandated lead arrangers; BNP Paribas, DBS Bank Ltd., IYO Bank, Societe Generale and UOB as the lead arrangers; Commercial Bank Ltd., Singapore Branch, Skandinaviska Enskilda Banken AB (publ) and Taishin International Bank, Singapore Branch, as co-arrangers. ING served as the Facility Coordinator and Facility Agent for the transaction. By refinancing existing debt with this Loan Facility, Hafnia has lowered its overall cost of funding, reduced the cash flow breakeven, strengthened its liquidity profile and built in flexibility to position itself for future growth. The Loan Facility also has an uncommitted accordion tranche of up to USD 417 million to be exercised within two years. 'This facility is a testament to the confidence our banking partners have in Hafnia's strategy and performance. The lower cost, attractive terms and revolving nature of the facility gives us the agility to manage our liquidity needs and enhance our financial flexibility,' says Hafnia's CFO Perry van Echtelt. Stephen Fewster, ING's Global Head of Shipping, commented: 'We are proud to act as facility agent and to coordinate this innovative facility for an industry leader like Hafnia. The support from such a broad syndicate underlines Hafnia's reputation and the strong bank following which it has built.' About Hafnia Limited: Hafnia is one of the world's leading tanker owners, transporting oil, oil products and chemicals for major national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, we offer a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk. Hafnia has offices in Singapore, Copenhagen, Houston, and Dubai and currently employs over 4000 employees onshore and at sea. Hafnia is part of the BW Group, an international shipping group involved in oil and gas transportation, floating gas infrastructure, environmental technologies, and deep-water production for over 80 years. This information is subject to disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
Scoop
26-06-2025
- Automotive
- Scoop
Smarter Streets Ahead: AI Platform Sets Blueprint For Urban Innovation
A breakthrough in AI-powered traffic management is putting the future of city infrastructure on the fast track — and it's a vision that could soon be applied across cities in Australia and New Zealand. Milestone Systems has unveiled a next-gen video data platform, Project Hafnia, developed in partnership with NVIDIA and now rolling out in European cities following its inception in the US. At its core, Hafnia is designed to power smarter, safer and more efficient cities through ethically sourced and regulation-compliant video AI models — a concept equally applicable in the Southern Hemisphere. With traffic congestion, pedestrian safety, and public surveillance emerging as key challenges for growing urban centres across ANZ, Project Hafnia offers a roadmap for leveraging AI responsibly. The system uses NVIDIA's advanced GPU platforms and large-scale video datasets — both real and synthetic — to train visual language models (VLMs) that can help city officials understand traffic flows, detect hazards, or summarise surveillance footage for faster response. 'Our cities don't just need more data, they need better, smarter data,' said Thomas Jensen, CEO of Milestone. 'With Project Hafnia, we're building the digital foundation for cities that are safer, more transparent, and AI-enabled — without compromising public trust or privacy.' While currently operational in Genoa, Italy, the platform is built to scale globally. The opportunity for ANZ councils lies in adapting this blueprint to local conditions, unlocking better traffic coordination, real-time monitoring, and urban planning insights — all with compliance and citizen protection at its heart.
Yahoo
09-06-2025
- Business
- Yahoo
FDA approves YolTech's YOLT-101 for familial hypercholesterolemia
YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for YOLT-101 to treat heterozygous familial hypercholesterolemia (HeFH). YOLT-101 is an in vivo base editing therapy designed to target proprotein convertase subtilisin/kexin type 9 (PCSK9). Its innovative approach lies in its potential to durably reduce blood low-density lipoprotein cholesterol (LDL-C) levels through a single-dose treatment. The technology behind YOLT-101 incorporates YolTech's adenine base editor, known as hpABE5, which consists of nCas and a new deaminase evolved from Hafnia paralvei. To deliver this therapeutic agent, the company employs an advanced lipid nanoparticle (LNP) delivery system. hpABE5 can perform precise A•T to G•C base conversions without inducing DNA double-strand breaks, thus minimising risks associated with chromosomal abnormalities and off-target effects. YolTech Therapeutics co-founder and CEO Yuxuan Wu stated: 'The FDA IND clearance marks a significant milestone for YolTech. In vivo gene editing represents a new generation of therapeutics — offering one-time, durable solutions for chronic and genetic diseases. 'We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases.' Currently under evaluation in an ongoing investigator-initiated trial (IIT), YOLT-101 has shown promising results with a favourable safety profile and substantial LDL-C–lowering effects. Familial hypercholesterolemia is a genetic disorder stemming from mutations affecting LDL metabolism-related genes such as LDLR, Apolipoprotein B (APOB) and PCSK9. Individuals suffering from FH typically experience elevated LDL-C levels, which contribute to a heightened risk of developing early-onset atherosclerotic cardiovascular diseases. "FDA approves YolTech's YOLT-101 for familial hypercholesterolemia" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
09-06-2025
- Business
- Yahoo
FDA approves YolTech's YOLT-101 for familial hypercholesterolemia
YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for YOLT-101 to treat heterozygous familial hypercholesterolemia (HeFH). YOLT-101 is an in vivo base editing therapy designed to target proprotein convertase subtilisin/kexin type 9 (PCSK9). Its innovative approach lies in its potential to durably reduce blood low-density lipoprotein cholesterol (LDL-C) levels through a single-dose treatment. The technology behind YOLT-101 incorporates YolTech's adenine base editor, known as hpABE5, which consists of nCas and a new deaminase evolved from Hafnia paralvei. To deliver this therapeutic agent, the company employs an advanced lipid nanoparticle (LNP) delivery system. hpABE5 can perform precise A•T to G•C base conversions without inducing DNA double-strand breaks, thus minimising risks associated with chromosomal abnormalities and off-target effects. YolTech Therapeutics co-founder and CEO Yuxuan Wu stated: 'The FDA IND clearance marks a significant milestone for YolTech. In vivo gene editing represents a new generation of therapeutics — offering one-time, durable solutions for chronic and genetic diseases. 'We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases.' Currently under evaluation in an ongoing investigator-initiated trial (IIT), YOLT-101 has shown promising results with a favourable safety profile and substantial LDL-C–lowering effects. Familial hypercholesterolemia is a genetic disorder stemming from mutations affecting LDL metabolism-related genes such as LDLR, Apolipoprotein B (APOB) and PCSK9. Individuals suffering from FH typically experience elevated LDL-C levels, which contribute to a heightened risk of developing early-onset atherosclerotic cardiovascular diseases. "FDA approves YolTech's YOLT-101 for familial hypercholesterolemia" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
28-05-2025
- Business
- Yahoo
Are Options Traders Betting on a Big Move in Hafnia (HAFN) Stock?
Investors in Hafnia Limited HAFN need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $7.50 Put had some of the highest implied volatility of all equity options today. Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. Clearly, options traders are pricing in a big move for Hafnia shares, but what is the fundamental picture for the company? Currently, Hafnia is a Zacks Rank #3 (Hold) in the Transportation - Shipping industry that ranks in the Bottom 29% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while one analyst has revised the estimate downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from earnings of 21 cents per share to 14 cents in that the way analysts feel about Hafnia right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your to see the trades now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hafnia Limited (HAFN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
